Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine by Stearns Vered, Johnson Michael D, Rae James M, Morocho Alan, Novielli Antonella, Bhargava Pankaj, Hayes Daniel F, Desta Zeruesenay, Flockhart David A in Journal of the National Cancer Institute (2003). PubMed

Abstract

Tamoxifen, a selective estrogen receptor modulator (SERM), is converted to 4-hydroxy-tamoxifen and other active metabolites by cytochrome P450 (CYP) enzymes. Selective serotonin reuptake inhibitors (SSRIs), which are often prescribed to alleviate tamoxifen-associated hot flashes, can inhibit CYPs. In a prospective clinical trial, we tested the effects of coadministration of tamoxifen and the SSRI paroxetine, an inhibitor of CYP2D6, on tamoxifen metabolism.

[ hide abstract ]

Discussed In Paper